The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.
Bio & Medicine
Jun 13, 2011
1
1
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic ...
Biotechnology
Mar 2, 2011
0
0
Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only when patients also receive large doses of drugs designed to help immune cells multiply ...
Bio & Medicine
Sep 17, 2010
0
0
(PhysOrg.com) -- EphA4 is a protein which is attached to the surfaces of many types of human cells and plays a role in a wide range of biological processes. EphA4 functions by binding to ephrin ligands, cell surface proteins ...
Analytical Chemistry
Oct 23, 2009
0
0
Hollow gold nanospheres equipped with a targeting peptide find melanoma cells, penetrate them deeply, and then cook the tumor when bathed with near-infrared light, a research team led by scientists at The University of Texas ...
Bio & Medicine
Feb 2, 2009
1
0
